Literature DB >> 20520289

Long-term benzodiazepine use and salivary cortisol: the Netherlands Study of Depression and Anxiety (NESDA).

Leonie Manthey1, Erik J Giltay, Tineke van Veen, Arie Knuistingh Neven, Sophie A Vreeburg, Brenda W J H Penninx, Frans G Zitman.   

Abstract

BACKGROUND: As benzodiazepines (BZDs) have anxiolytic effects, it is expected that they influence the stress system. During short-term treatment, BZD use was found to suppress cortisol levels. However, little research has been done on the effects of long-term BZD administration on the hypothalamic-pituitary-adrenal (HPA) axis.
METHODS: The association between long-term BZD use and cortisol levels was investigated in subjects of the Netherlands Study of Depression and Anxiety with a lifetime diagnosis of anxiety or depression (n = 1531). The subjects were categorized as "daily BZD users" (n = 96), "infrequent BZD users" (n = 172), and "nonusers" (n = 1263). Possible associations between characteristics of BZD use (dose, duration, and dependence) and salivary cortisol levels were analyzed. MAIN OUTCOME MEASURE: Subjects provided 7 saliva samples, from which 4 cortisol indicators were calculated: the cortisol awakening response, diurnal slope, evening cortisol, and cortisol suppression after ingestion of 0.5 mg of dexamethasone.
RESULTS: Daily users used BZDs for a median duration of 26.5 months and had a median daily dosage of 6.0 mg as measured in diazepam equivalents. Evening cortisol levels were significantly lower in daily users (P = 0.004; effect size: d = 0.24) and infrequent users (P = 0.04; effect size: d = 0.12) compared to nonusers. We did not find significant differences in the cortisol awakening response, diurnal slope, or in the dexamethasone suppression test.
CONCLUSIONS: Despite the finding of slightly lower evening cortisol levels in daily and infrequent BZD users compared to nonusers, results indicate that long-term BZD use is not convincingly associated with HPA axis alterations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520289     DOI: 10.1097/JCP.0b013e3181d41f41

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

1.  The role of melatonin and cortisol circadian rhythms in the pathogenesis of infantile colic.

Authors:  Tolga İnce; Hakkı Akman; Dilek Çimrin; Adem Aydın
Journal:  World J Pediatr       Date:  2018-03-05       Impact factor: 2.764

2.  Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA).

Authors:  Leonie Manthey; Tineke van Veen; Erik J Giltay; José E Stoop; Arie Knuistingh Neven; Brenda W J H Penninx; Frans G Zitman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

3.  Challenges in Obtaining and Assessing Salivary Cortisol and α-Amylase in an Over 60 Population Undergoing Psychotherapeutic Treatment for Complicated Grief: Lessons Learned.

Authors:  Jesse M Bell; Tina M Mason; Harleah G Buck; Cindy S Tofthagen; Allyson R Duffy; Maureen W Groër; James P McHale; Kevin E Kip
Journal:  Clin Nurs Res       Date:  2020-11-20       Impact factor: 2.075

4.  Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): observational study protocol.

Authors:  Carlos A Soria; Carolina Remedi; Daniel A Núñez; Luciana D'Alessio; Emilio J A Roldán
Journal:  BMJ Open       Date:  2015-07-14       Impact factor: 2.692

5.  Imepitoin Shows Benzodiazepine-Like Effects in Models of Anxiety.

Authors:  Odilo Engel; Aleksandar Masic; Gary Landsberg; Melissa Brooks; Daniel S Mills; Chris Rundfeldt
Journal:  Front Pharmacol       Date:  2018-11-01       Impact factor: 5.810

6.  Changes in Cortisol but Not in Brain-Derived Neurotrophic Factor Modulate the Association Between Sleep Disturbances and Major Depression.

Authors:  Giuliana Travassos Pires Santiago; Ana Cecília de Menezes Galvão; Raíssa Nóbrega de Almeida; Sergio Arthuro Mota-Rolim; Fernanda Palhano-Fontes; João Paulo Maia-de-Oliveira; Dráulio Barros de Araújo; Bruno Lobão-Soares; Nicole Leite Galvão-Coelho
Journal:  Front Behav Neurosci       Date:  2020-04-28       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.